Medical Cannabis During Chemoradiation for Head and Neck Cancer

Inclusion Criteria: * Patients must have histologically confirmed squamous cell carcinoma of the head and neck region planned for definitive or adjuvant treatment with concurrent radiation therapy and systemic therapy * Patients may receive platinum-based chemotherapy or cetuximab concurrently with radiation therapy * Age \>18 years and ECOG performance status \<2 (Karnofsky \>60). * Patients must be willing to use medically certified cannabis as directed after study enrollment * Patients must be able to read English, Spanish, or French fluently * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Prior diagnosis of cannabis use disorder as defined in the DSM-V * Current opioid use disorder on maintenance opioid therapy * Current active use of smoked cannabis or cannabis derivatives AND unwillingness to cease use of non-medically certified cannabis for the duration of study participation. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cannabis derivatives * Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.